AGA临床实践更新:肝细胞癌风险分层与监测策略
该专家综述由AGA临床实践更新委员会委托,提供关于肝细胞癌风险分层和监测策略的最佳实践建议。当前推荐每半年超声联合甲胎蛋白监测,但敏感性欠佳;非病毒性肝病HCC负担上升,需更好生物标志物和风险分层工具,但新型标志物证据不足,不推荐常规使用。
要点
- 预防肝硬化是降低HCC发病和死亡的最佳策略。
- 当前首选监测策略为每半年超声联合甲胎蛋白。
- 新型血液或影像生物标志物证据不足,不推荐常规替代指南检测。
核心结论
- 预防肝硬化是减少HCC morbidity和mortality的最佳策略。
- 当前首选监测策略为每半年超声联合甲胎蛋白。
- 新型生物标志物证据不足,不推荐常规用于HCC监测。
研究设计与样本
- 本专家综述由AGA临床实践更新委员会委托并批准,经内部和外部同行评议,基于文献回顾和专家意见制定最佳实践建议,未进行系统评价。
主要发现
- 当前指南推荐每半年超声联合甲胎蛋白监测,但策略敏感性欠佳且不足1/4肝硬化患者接受监测。
- HCC负担在非病毒性肝病(如代谢功能障碍相关脂肪性肝病和酒精相关肝病)中上升最快,年发病率显著低于病毒性肝炎。
- 新型血液生物标志物如GALAD和影像生物标志物正在临床验证,部分已商用但证据不足支持常规使用。
- 多癌血液生物标志物检测面板不应用于HCC筛查或监测。
- 许多肝硬化HCC风险分层评分缺乏足够验证支持临床使用。
关键数值与推荐
- 最佳实践建议1:预防肝硬化策略包括疫苗接种和治疗病毒性肝炎、识别和治疗酒精使用障碍、管理代谢综合征及早期处理肝病。
- 最佳实践建议2:当前首选监测策略为每半年超声联合甲胎蛋白。
- 最佳实践建议3:无肝硬化患者中仅部分慢性乙型肝炎病毒感染者应监测;其他病因无肝硬化者不推荐监测。
- 最佳实践建议5:新型生物标志物证据不足支持常规HCC监测,不应替代指南推荐检测。
- 最佳实践建议8:无肝硬化慢性HBV感染者可用PAGE-B和REAL-B评分进行风险分层。
临床怎么用
- 临床应优先预防肝硬化,并对肝硬化(任何病因)和选定慢性HBV感染者进行每半年超声联合甲胎蛋白监测。
- 考虑监测的潜在身体、心理和经济伤害。
- 不常规使用新型生物标志物或多癌血液检测面板进行HCC监测。
- 无肝硬化慢性HBV感染者可使用PAGE-B和REAL-B评分分层风险。
局限性
- 未进行系统评价,最佳实践建议无正式证据质量或推荐强度评级。
- 新型生物标志物和风险分层评分证据不足支持常规临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in patients with cirrhosis. Although advancements in surgical, locoregional, and systemic therapies have improved outcomes for patients with early-stage HCC, most cases are diagnosed at later stages due to both the limitations of currently recommended surveillance modalities and their underuse, with fewer than 1 in 4 patients with cirrhosis receiving surveillance for this tumor. Current guidelines recommend semiannual surveillance with ultrasound and α-fetoprotein, but this strategy has suboptimal sensitivity, and alternative imaging techniques (eg, computed tomography and magnetic resonance imaging) have their own risks and challenges with implementation. HCC surveillance has established benefits in certain at-risk populations, including patients with cirrhosis (of any etiology) and selected patients with chronic hepatitis B virus. The burden of HCC is rising most rapidly among patients with nonviral liver diseases, including metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease, among whom the annual incidence rate of HCC is significantly lower than was previously observed in patients with viral hepatitis. This underscores the need for better biomarker and risk-stratification tools to detect HCC earlier and improve surveillance efficiency, although integrating them into routine clinical practice presents a significant challenge. This American Gastroenterological Association (AGA) Clinical Practice Update aims to provide Best Practice Advice on emerging strategies for HCC risk stratification and surveillance. METHODS: This Expert Review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on this topic of high clinical importance to the AGA membership and underwent internal peer review by the Clinical Practice Updates Committee and external review procedures through the standard review process for Gastroenterology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Because a systematic review was not performed, these Best Practice Advice statements do not carry formal ratings of the quality of available evidence or the strength of the presented advice. Best Practice Advice Statements BEST PRACTICE ADVICE 1: The best strategy for reducing hepatocellular carcinoma morbidity and mortality is to prevent cirrhosis. These strategies include vaccination and treatment of viral hepatitis (eg, hepatitis C virus and hepatitis B virus), recognizing and treating alcohol use disorder, managing metabolic syndrome, and addressing liver diseases at early stages. BEST PRACTICE ADVICE 2: The preferred current surveillance strategy for patients at risk of hepatocellular carcinoma is semiannual ultrasound and α-fetoprotein in combination. The benefits of surveillance include a higher likelihood of detecting early-stage hepatocellular carcinoma, access to curative therapy, and improved survival. BEST PRACTICE ADVICE 3: Among patients without cirrhosis, only a subset of those with chronic hepatitis B virus should undergo hepatocellular carcinoma surveillance; surveillance is not advised for those without cirrhosis from other etiologies due to the low annual incidence rate. BEST PRACTICE ADVICE 4: Although the benefits of hepatocellular carcinoma surveillance are well established, it is important for clinicians to consider the potential physical, psychological, and financial harms associated with the process. BEST PRACTICE ADVICE 5: Several novel blood-based biomarkers, such as GALAD, and radiologic biomarkers are undergoing clinical validation. Some are already commercially available, but evidence is insufficient to support their use in routine hepatocellular carcinoma surveillance. These assays should not replace guideline-recommended tests, although their accessibility and potential cost-effectiveness may support broader use once sufficiently validated. BEST PRACTICE ADVICE 6: Multicancer blood-based biomarker detection panels should not be used in the screening or surveillance of patients at risk for hepatocellular carcinoma. BEST PRACTICE ADVICE 7: Many hepatocellular carcinoma risk-stratification scores exist for patients with cirrhosis. However, few scores have undergone sufficient validation to support their use in clinical practice. BEST PRACTICE ADVICE 8: Among patients with chronic hepatitis B virus infection without cirrhosis, PAGE-B and REAL-B scores can stratify patients based on their future risk of hepatocellular carcinoma.
引用
- Rich NE, Villanueva A, Marrero JA, et al. AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review. Gastroenterology. 2026. PMID: 42017860. doi:10.1053/j.gastro.2026.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。